Medicaid coverage for weight loss medication depends almost entirely on which state you live in, and most states don’t cover it. As of mid-2024, only 13 states covered GLP-1 medications for weight loss in adults through their fee-for-service Medicaid programs. Federal law includes weight loss drugs in a small category of medications that states can exclude from coverage, so there is no national guarantee you’ll have access to these prescriptions through Medicaid.
Why Most States Don’t Cover Weight Loss Drugs
The Medicaid Drug Rebate Program requires states to cover most FDA-approved medications from manufacturers that participate in the rebate program. But there’s a specific carve-out in federal law (42 U.S.C. § 1396r-8) that allows states to exclude drugs used for “anorexia, weight loss, or weight gain.” This exception has been in place for decades, and it means each state individually decides whether to add weight loss medications to its formulary.
Because GLP-1 weight loss drugs like Wegovy and Zepbound can cost over $1,000 per month, many states have been reluctant to open coverage. Some states that previously covered these drugs have pulled back. Pennsylvania, for example, eliminated Medicaid coverage of GLP-1s for weight loss starting in January 2026. Other states may follow as budgets tighten.
The Diabetes Loophole
Here’s where it gets confusing. The same active ingredients used in weight loss drugs are also sold under different brand names for Type 2 diabetes. Semaglutide is marketed as Wegovy for weight loss and Ozempic for diabetes. Tirzepatide is sold as Zepbound for weight loss and Mounjaro for diabetes. Most state Medicaid programs cover the diabetes versions because diabetes drugs don’t fall under the weight loss exclusion.
This means if you have Type 2 diabetes, your Medicaid plan will likely cover a GLP-1 medication prescribed for blood sugar management. The weight loss you experience would be a side effect of the diabetes treatment rather than the stated purpose of the prescription. But if your only diagnosis is obesity, without diabetes, coverage becomes far less certain.
Which Medications Are Considered
When states do cover weight loss drugs, they typically evaluate two categories. Newer-generation medications include Wegovy (semaglutide), Saxenda (liraglutide), and Zepbound (tirzepatide). Older-generation medications include Contrave, Qsymia, phentermine, benzphetamine, diethylpropion, and phendimetrazine. States that offer coverage usually include at least some options from both categories.
Over-the-counter options like orlistat (sold as Alli or formerly as prescription Xenical) sit in a gray area. Some states that technically “cover” obesity medications only cover these OTC drugs, which you could buy yourself at a pharmacy without a prescription. Researchers tracking state coverage rank these states at the lowest tier of coverage, essentially a token offering.
The most comprehensive state programs cover at least one newer-generation drug (like Wegovy) and at least one older-generation drug (like phentermine) specifically for the purpose of treating obesity, not just as a secondary benefit of diabetes treatment.
What Prior Authorization Looks Like
Even in states that cover weight loss medications, you won’t simply get a prescription filled. Nearly every state requires prior authorization, a process where your doctor submits paperwork proving you meet specific clinical criteria before the pharmacy can dispense the drug.
North Carolina’s criteria offer a representative example of what states typically require. For adults, you need either a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, Type 2 diabetes, sleep apnea, heart disease, or high cholesterol. Adolescents ages 12 to 17 must have a BMI at or above the 95th percentile for their age and sex, or meet lower BMI thresholds combined with a serious weight-related condition.
Your doctor must document your current weight and BMI from within the past 45 days. You also need to be actively participating in lifestyle changes, including structured nutrition and physical activity, unless your doctor documents that exercise isn’t clinically appropriate for you at that time. You cannot use the weight loss drug alongside another GLP-1 medication.
Step Therapy Requirements
Most states also require step therapy, meaning you have to try the state’s preferred (usually cheaper) drug first before you can get approved for a more expensive alternative. In North Carolina, Wegovy is the preferred product. If you want Zepbound or Saxenda instead, you need to show that you tried Wegovy for three to six months and either experienced side effects or didn’t respond adequately, or that you have a documented medical reason you can’t take it. The titration period alone for GLP-1 medications can take up to six months, so getting approved for a non-preferred drug is a slow process.
Managed Care Plans May Differ
Most Medicaid beneficiaries today are enrolled in managed care organizations (MCOs) rather than traditional fee-for-service Medicaid. These are private insurance companies that contract with the state to manage your benefits. The state pays them a fixed monthly amount per enrollee, and the MCO decides how to allocate that money across covered services.
This matters because your MCO may have different drug coverage rules than the state’s fee-for-service program. Some states carve prescription drugs out of managed care entirely, handling them through the state’s own pharmacy benefit. Others let each MCO manage its own drug formulary within state guidelines. That means two people on Medicaid in the same state could have different coverage for weight loss drugs depending on which managed care plan they’re assigned to. Checking your specific plan’s preferred drug list is the only reliable way to know what’s available to you.
What You’ll Pay Out of Pocket
If your state does cover weight loss medication, your copay will be low. Medicaid limits out-of-pocket costs to nominal amounts for most enrollees. For preferred drugs, the maximum copay is $4. For non-preferred drugs, it’s $8 for people with income at or below 150% of the federal poverty level. People with higher incomes may pay up to 20% of what the state pays for the drug, but total out-of-pocket spending across all services is capped at 5% of family income. Compared to the retail price of these medications, which can run $1,000 or more monthly, Medicaid copays are minimal once you clear the prior authorization hurdle.
Coverage Is Shifting Fast
The landscape for Medicaid weight loss drug coverage is unusually volatile right now. States are adding and removing coverage on short timelines as drug costs, political pressures, and budget realities collide. North Carolina reinstated coverage for GLP-1 weight loss drugs in December 2025 after temporarily suspending it, adding Wegovy, Zepbound, and Saxenda back to its preferred drug list following a governor’s directive. Meanwhile, Pennsylvania moved in the opposite direction, cutting coverage starting in 2026.
Your best starting point is your state Medicaid agency’s website or your managed care plan’s drug formulary, which will list currently covered medications and any prior authorization requirements. The STOP Obesity Alliance at George Washington University also publishes annual state-by-state coverage reports that can help you understand where your state stands relative to others.